Why Quoin Pharmaceuticals Is Rising In Pre-market?
I'm PortAI, I can summarize articles.
Quoin Pharmaceuticals (QNRX) has seen an 8% rise in pre-market trading following the FDA's grant of Orphan Drug Designation for its lead product candidate, QRX003, aimed at treating Netherton Syndrome. This designation complements a similar one from the European Medicines Agency in May 2025. QRX003 is currently undergoing pivotal clinical trials, with enrollment expected to finish in Q1 2026 and top-line data anticipated in the latter half of 2026, leading to an NDA submission later that year.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments